合計 50 件の最近のインサイダー取引記録が記録されています Xilio Therapeutics, Inc. (XLO), 内訳は 36 件の買い および 11 件の売り. インサイダー買い総額は $14.86M インサイダー売り総額は $12.1M.
最近活動のある主要インサイダーには Shannon James Samuel, Gilead Sciences, Inc., Brennan Kevin M.. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — XLO
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-03-26 |
Shannon James Samuel |
Director |
情報に基づく買い |
5,000 |
$8.79 |
$43.95K |
10,000 |
| 2026-02-13 |
Gilead Sciences, Inc. |
10 Percent Owner |
情報に基づく買い |
3,739,000 |
$0.00 |
$373.90 |
40,384,266 |
| 2026-01-02 |
Brennan Kevin M. |
SVP, Finance and Accounting |
情報に基づく売り |
1,826 |
$0.64 |
$1.17K |
6,371 |
| 2026-01-02 |
Frankenfield Christopher James |
Chief Financial Officer |
情報に基づく売り |
7,030 |
$0.64 |
$4.52K |
24,766 |
| 2026-01-01 |
Russo Rene |
President and CEO |
オプション行使（売却） |
44,250 |
- |
- |
88,500 |
| 2026-01-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
オプション行使 |
5,000 |
- |
- |
8,197 |
| 2026-01-01 |
Frankenfield Christopher James |
Chief Financial Officer |
オプション行使 |
19,375 |
- |
- |
31,796 |
| 2026-01-01 |
Luptakova Katarina |
Chief Medical Officer |
オプション行使 |
16,625 |
- |
- |
33,250 |
| 2025-12-31 |
Russo Rene |
President and CEO |
RSU 付与（制限付株式） |
1,500,258 |
$0.84 |
$1.26M |
1,500,258 |
| 2025-12-31 |
Brennan Kevin M. |
SVP, Finance and Accounting |
RSU 付与（制限付株式） |
95,221 |
$0.84 |
$80.08K |
95,221 |
| 2025-12-31 |
Frankenfield Christopher James |
Chief Financial Officer |
RSU 付与（制限付株式） |
668,789 |
$0.84 |
$562.45K |
668,789 |
| 2025-12-31 |
Luptakova Katarina |
Chief Medical Officer |
RSU 付与（制限付株式） |
451,885 |
$0.84 |
$380.04K |
451,885 |
| 2025-11-26 |
Gilead Sciences, Inc. |
10 Percent Owner |
オプション行使（ITM） |
13,335,000 |
$0.75 |
$10M |
- |
| 2025-11-21 |
Russo Rene |
President and CEO |
株式返還 |
135,134 |
$11.69 |
$1.58M |
- |
| 2025-11-21 |
Brennan Kevin M. |
SVP, Finance and Accounting |
株式返還 |
20,000 |
$1.08 |
$21.6K |
- |
| 2025-11-21 |
Frankenfield Christopher James |
Chief Financial Officer |
株式返還 |
150,000 |
$2.75 |
$412.5K |
- |
| 2025-11-21 |
Luptakova Katarina |
Chief Medical Officer |
株式返還 |
25,000 |
$2.79 |
$69.63K |
- |
| 2025-06-17 |
Shannon James Samuel |
Director |
情報に基づく買い |
25,000 |
$0.69 |
$17.22K |
70,000 |
| 2025-06-16 |
Shannon James Samuel |
Director |
情報に基づく買い |
45,000 |
$0.69 |
$30.87K |
45,000 |
| 2025-06-16 |
Russo Rene |
President and CEO |
情報に基づく買い |
36,289 |
$0.68 |
$24.68K |
281,172 |
| 2025-06-11 |
Clancy Paul J |
Director |
RSU 付与（制限付株式） |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Shannon James Samuel |
Director |
RSU 付与（制限付株式） |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Bonstein Sara |
Director |
RSU 付与（制限付株式） |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Brennan Aoife |
Director |
RSU 付与（制限付株式） |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Ross Robert W. |
Director |
RSU 付与（制限付株式） |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Rossi Christina |
Director |
RSU 付与（制限付株式） |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Xu Yuan |
Director |
RSU 付与（制限付株式） |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Curran Daniel J. |
Director |
RSU 付与（制限付株式） |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-10 |
Bello Akintunde Olatokumbo |
Officer |
不明 |
- |
- |
- |
- |
| 2025-06-10 |
Bello Akintunde Olatokumbo |
Director |
RSU 付与（制限付株式） |
62,000 |
$0.70 |
$43.4K |
62,000 |
| 2025-06-05 |
Gilead Sciences, Inc. |
10 Percent Owner |
情報に基づく買い |
13,335,000 |
$0.75 |
$10M |
13,335,000 |
| 2025-04-15 |
Russo Rene |
President and CEO |
RSU 付与（制限付株式） |
190,000 |
$0.71 |
$135.28K |
190,000 |
| 2025-04-15 |
Frankenfield Christopher James |
Chief Financial Officer |
RSU 付与（制限付株式） |
75,000 |
$0.71 |
$53.4K |
75,000 |
| 2025-01-02 |
Brennan Kevin M. |
SVP, Finance and Accounting |
情報に基づく売り |
1,803 |
$0.98 |
$1.77K |
3,197 |
| 2025-01-02 |
Frankenfield Christopher James |
Chief Financial Officer |
情報に基づく売り |
6,954 |
$0.98 |
$6.84K |
12,421 |
| 2025-01-01 |
Russo Rene |
President and CEO |
オプション行使（売却） |
44,250 |
- |
- |
132,750 |
| 2025-01-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
オプション行使 |
5,000 |
- |
- |
5,000 |
| 2025-01-01 |
Frankenfield Christopher James |
Chief Financial Officer |
オプション行使 |
19,375 |
- |
- |
19,375 |
| 2025-01-01 |
Luptakova Katarina |
Chief Medical Officer |
オプション行使 |
16,625 |
- |
- |
16,625 |
| 2025-01-01 |
Russo Rene |
Officer |
不明 |
- |
- |
- |
- |
| 2024-12-18 |
Gilead Sciences, Inc. |
10 Percent Owner |
情報に基づく買い |
1,759,978 |
$1.04 |
$1.83M |
9,105,451 |
| 2024-10-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
RSU 付与（制限付株式） |
26,000 |
$0.75 |
$19.5K |
26,000 |
| 2024-08-03 |
Frankenfield Christopher James |
Chief Operating Officer |
RSU 付与（制限付株式） |
52,000 |
$0.90 |
$46.54K |
52,000 |
| 2024-06-14 |
Clancy Paul J |
Director |
RSU 付与（制限付株式） |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Bonstein Sara |
Director |
RSU 付与（制限付株式） |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Ross Robert W. |
Director |
RSU 付与（制限付株式） |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Rossi Christina |
Director |
RSU 付与（制限付株式） |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Xu Yuan |
Director |
RSU 付与（制限付株式） |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Curran Daniel J. |
Director |
RSU 付与（制限付株式） |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-13 |
Shannon James Samuel |
Officer |
不明 |
- |
- |
- |
- |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
